Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2022-03-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
2021年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report and financial statements for the fiscal year 2021, covering the period from January 1, 2021 to December 31, 2021. It includes an auditor's opinion, detailed audit procedures, key audit matters, and comprehensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an auditor's report with registration numbers and detailed financial data confirms this is a full audit report with financial statements, not just an announcement or certification. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief notice. Therefore, the document fits the category of Audit Report / Information (AR). FY 2021
2022-03-25 Chinese
2021年年度报告（已取消）
Annual Report Classification · 100% confidence The document is titled "天津瑞普生物技术股份有限公司 2021 年年度报告全文" which translates to "Tianjin Ringpu Biotechnology Co., Ltd. 2021 Annual Report Full Text." It contains detailed sections such as company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management analysis, and detailed business descriptions, consistent with a full annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-03-25 Chinese
2021年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled '2021 年度董事会工作报告' which translates to '2021 Annual Board of Directors Work Report'. It contains detailed information about the company's business performance during the year 2021, including financial figures such as revenue, net profit, asset totals, and cash flow. It also discusses the operation of the board of directors, meetings held, decisions made, and committee activities. The document includes a profit distribution plan and outlines the board's work plan for 2022. The content is comprehensive and covers the company's yearly activities and financial performance, typical of a management report or annual report. However, it is specifically a 'Board of Directors Work Report' which is a type of management report explaining the board's activities and company performance over the year. It is not a full Annual Report (10-K) but a detailed management report from the board. Therefore, the most appropriate classification is 'Management Reports (MDA)'. The document length (6562 characters) supports it being a substantive report rather than a brief announcement or certification.
2022-03-25 Chinese
监事会决议公告
Annual Report Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 32nd meeting of the 4th Supervisory Board of Tianjin Ruipu Biotechnology Co., Ltd. It discusses approval of the 2021 Annual Report, 2021 Supervisory Board Work Report, 2021 Audited Financial Report, 2021 Financial Final Accounts Report, profit distribution plan, and other related reports. It references the 2021 fiscal year and includes substantive financial data such as revenue, net profit, assets, liabilities, and cash flow figures. The document also mentions the need to submit these reports to the 2021 Annual General Meeting for approval. The content is comprehensive and includes financial results and management decisions, consistent with an Annual Report or equivalent comprehensive yearly report. It is not merely an announcement of report publication or a brief summary but contains detailed financial and operational data. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-03-25 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司预计2022年度日常关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from China Galaxy Securities Co., Ltd. regarding the expected 2022 annual related party transactions of Tianjin Ruipu Biotechnology Co., Ltd. It includes extensive information on the nature, amounts, counterparties, pricing principles, and approvals related to these related party transactions. The document also contains opinions from independent directors, the supervisory board, and the sponsor institution, confirming compliance with relevant laws and regulations. The content is substantive, detailed, and focused on the company's related party transactions for the fiscal year 2022, which is a typical subject of regulatory filings related to connected transactions. It is not an annual report, earnings release, or management discussion, nor is it a simple announcement or certification. Given the focus on related party transactions and the detailed nature of the report, this fits best under the category of Regulatory Filings (RNS), which covers compliance documents and miscellaneous filings that do not fit other categories, especially since there is no specific category for related party transaction disclosures in the provided list.
2022-03-25 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司2021年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2021年度跟踪报告' (2021 Annual Tracking Report) issued by a sponsoring institution (中国银河证券股份有限公司) regarding 天津瑞普生物技术股份有限公司. It details the sponsor's review and supervision activities, company governance, compliance with commitments, and other oversight matters. The content focuses on monitoring and supervisory work rather than presenting full financial statements or comprehensive annual financial performance. The document length is relatively short (2228 characters), and it does not contain detailed financial data or audited financial statements. It is a report on sponsor's tracking and oversight activities, which aligns with the nature of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or Interim Report (IR). It is not an announcement or publication notice, nor a certification or regulatory filing. Therefore, the best fit is Audit Report / Information (AR). FY 2021
2022-03-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.